GLYCOPREP
Post-LOEpolyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous
ANDAORALFOR SUSPENSION
Approved
Dec 1988
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GLYCOPREP (polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous) by Agepha Pharma is 3350 which causes water to be retained in the colon and produces a watery stool. First approved in 1988.
Drug data last refreshed 18h ago
Mechanism of Action
3350 which causes water to be retained in the colon and produces a watery stool
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on GLYCOPREP at Agepha Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.